Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21702748 | 0.89 | NR1H2 (0.42) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL21699892 | 0.89 | NR1H2 (0.42) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL25635593 | 0.89 | NR1H2 (0.42) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL21748959 | 0.88 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL21748956 | 0.88 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL31240033 | 0.88 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL21748957 | 0.88 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL31239821 | 0.86 | HSD17B10 (0.40) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL8274531 | 0.85 | SMN1; SMN2 (0.43) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL13344518 | 0.85 | SMN1; SMN2 (0.43) | HSD17B10SMN1; SMN2CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737160-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7737160-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBVIE INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBVIE INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABL1, ERBB2, LCK | HSD17B10 4179/4885SMN1; SMN2 4269/4885CHRM2 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.